Browse > Article
http://dx.doi.org/10.5483/BMBRep.2015.48.1.042

Upregulation of Fas in epithelial ovarian cancer reverses the development of resistance to Cisplatin  

Fan, Yang (Department of Obstetrics and Gynecology, Ningxia People's Hospital)
Wang, Long (Ningxia Medical University)
Han, Xuechuan (Department of Obstetrics and Gynecology, Ningxia People's Hospital)
Liu, Xueqin (Department of Obstetrics and Gynecology, Ningxia People's Hospital)
Ma, Hongyun (Department of Obstetrics and Gynecology, Ningxia People's Hospital)
Ding, Yonghui (Affiliated Hospital of Ningxia Medical University)
Publication Information
BMB Reports / v.48, no.1, 2015 , pp. 30-35 More about this Journal
Abstract
This study was to investigate the role of Fas in the development of Cisplatin-resistant ovarian cancer. On the cellular level, Fas expression was significantly reduced in Cisplatin resistant A2780 (A2780/CP) cells compared with A2780 cells. Fas silence with siRNA would promote tumor cell lines proliferation, facilitate tumor cell cycle transition of G1/S, prevent cell apoptosis, and promote cell migration. Expression of drug resistance gene was negatively correlated to Fas. In nude mice metastasis model of human ovarian carcinoma by subcutaneous transplantation, after Ad-Fas injected intratumorly, we found that upregulation of Fas could inhibit transplantation tumor tissue growth and reduce the expression of drug resistance gene. Our results indicated that upregulation of Fas in epithelial ovarian cancer reversed the development of resistance to Cisplatin. In conclusion, our findings suggested that Fas might act as a promising therapeutic target for improvement of the sensibility to Cisplatin in ovarian cancer.
Keywords
A2780/CP cell; Cisplatin-resistance; Epithelial ovarian cancer; Fas; Oncotherapy;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Zhou W, Han WF, Landree LE et al (2007) Fatty acid synthase inhibition activates AMP-activated protein kinase in SKOV3 human ovarian cancer cells. Cancer Res 67, 2964-2971   DOI   ScienceOn
2 Wu W, Wang HD, Guo W et al (2010) Up-regulation of Fas reverses Cisplatin resistance of human small cell lung cancer cells. J Exp Clin Cancer Res 29, 49   DOI   ScienceOn
3 Yamaguchi H, Wyckoff J and Condeelis J (2005) Cell migration in tumors. Curr Opin Cell Biol 17, 559-564   DOI   ScienceOn
4 Yap TA, Carden CP and Kaye SB (2009) Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer 9, 167-181   DOI   ScienceOn
5 Behrens BC, Hamilton TC, Masuda H et al (1987) Characterization of a cis-diamminedichloroplatinum(II)- resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res 47, 414-418
6 Liu WH and Chang LS (2011) Fas/FasL-dependent and -independent activation of caspase-8 in doxorubicin-treated human breast cancer MCF-7 cells: ADAM10 down-regulation activates Fas/FasL signaling pathway. Int J Biochem Cell Biol 43, 1708-1719   DOI   ScienceOn
7 Stefansson OA, Villanueva A, Vidal A, Martí L and Esteller M (2012) BRCA1 epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast and ovarian cancer. Epigenetics 7, 1225-1229   DOI
8 Lin C, Zhao XY, Li L et al (2012) NOXA-induced alterations in the Bax/Smac axis enhance sensitivity of ovarian cancer cells to Cisplatin. PLoS One 7, e36722   DOI
9 Johnson SW, Laub PB, Beesley JS, Ozols RF and Hamilton TC (1997) Increased platinum-DNA damage tolerance is associated with Cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines. Cancer Res 57, 850-856
10 Siddik ZH (2003) Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22, 7265-7279   DOI   ScienceOn
11 Locksley RM, Killeen N and Lenardo MJ (2001) The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 104, 487-501   DOI   ScienceOn
12 Desbarats J, Birge RB, Mimouni-Rongy M, Weinstein DE, Palerme JS and Newell MK (2003) Fas engagement induces neurite growth through ERK activation and p35 upregulation. Nat Cell Biol 5,118-125   DOI   ScienceOn
13 Golubovskaya VM, Kweh FA and Cance WG (2009) Focal adhesion kinase and cancer. Histol Histopathol 24, 503-510
14 Kuhajda FP (2006) Fatty acid synthase and cancer: new application of an old pathway. Cancer Res 66, 5977-5980   DOI   ScienceOn
15 Halder J, Lin YG, Merritt WM et al (2007) Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma. Cancer Res 67, 10976-10983   DOI   ScienceOn
16 Zhou W, Han WF, Landree LE et al (2007) Fatty acid synthase inhibition activates AMP-activated protein kinase in SKOV3 human ovarian cancer cells. Cancer Res 67, 2964-2971   DOI   ScienceOn
17 Jemal A, Siegel R, Ward E, Murray T, Xu J and Thun MJ. (2007) Cancer statistics. CA Cancer J Clin 57, 43-66   DOI   ScienceOn
18 Broxterman HJ, Gotink KJ and Verheul HM (2009) Understanding the causes of multidrug resistance in cancer: a comparison of doxorubicin and sunitinib. Drug Resist Updat 12, 114-126   DOI   ScienceOn
19 Song IS, Savaraj N, Siddik ZH et al (2004) Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in Cisplatin-sensitive and Cisplatin-resistant cells. Mol Cancer Ther 3, 1543-1549
20 Bivona TG, Hieronymus H, Parker J et al (2011) FAS and NF-kappaB signalling modulate dependence of lung cancers on mutant EGFR[J]. Nature 471, 523-526   DOI   ScienceOn
21 Caldecott KW, Tucker JD and Thompson LH (1992) Construction of human XRCC1 minigenes that fully correct the CHO DNA repair mutant EM9. Nucleic Acids Res 20, 4575-4579   DOI   ScienceOn
22 Li P, Lin Y, Zhang Y, Zhu Z and Huo K (2013) SSX2IP promotes metastasis and chemotherapeutic resistance of hepatocellular carcinoma. J Transl Med 11, 52   DOI
23 Cai X, Stoicov C, Li H et al (2005) Overcoming Fas-mediated apoptosis accelerates Helicobacter-induced gastric cancer in mice. Cancer Res 65, 10912-10920   DOI   ScienceOn
24 Fauvet R, Dufournet C, Poncelet C, Uzan C, Hugol D and Daraï E (2005) Expression of pro-apoptotic (p53, p21, bax, bak and fas) and anti-apoptotic (bcl-2 and bcl-x) proteins in serous versus mucinous borderline ovarian tumours. J Surg Oncol 92, 337-343   DOI   ScienceOn